Avoidance of routine revascularization in the management of patients with non-ST-segment elevation acute coronary syndromes
A debate continues over whether a routine invasive or a conservative strategy is the best treatment approach for patients with non–ST-segment elevation acute coronary syndrome. The fundamental question underlying this debate is whether risk stratification should be an anatomy-driven or an ischemia-d...
Gespeichert in:
Veröffentlicht in: | The American journal of cardiology 2000-12, Vol.86 (12), p.42-47 |
---|---|
1. Verfasser: | |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 47 |
---|---|
container_issue | 12 |
container_start_page | 42 |
container_title | The American journal of cardiology |
container_volume | 86 |
creator | Boden, William E |
description | A debate continues over whether a routine invasive or a conservative strategy is the best treatment approach for patients with non–ST-segment elevation acute coronary syndrome. The fundamental question underlying this debate is whether risk stratification should be an anatomy-driven or an ischemia-driven process. An early routine invasive or “drive-through” strategy, which consists of cardiac catheterization followed by percutaneous coronary intervention within 24 hours of the onset of angina, has not been shown to result in improved outcomes. In fact, investigators in the Veterans Affairs Non–Q-Wave Infarction Strategies in Hospital (VANQWISH) trial found that aggressively treated patients had significantly worse outcomes during the first year of follow-up than did those treated with a conservative strategy. In this overview, a conservative (ischemia-guided) strategy with aggressive medical therapy is recommended for patients with non–ST-segment elevation acute coronary syndrome. This conservative treatment includes intensive antiplatelet, antithrombotic, and anti-ischemic therapy combined with careful clinical assessment and provocative testing. Patients undergo catheterization and revascularization only if spontaneous angina occurs or there is objective evidence of stress-induced myocardial ischemia. In the future, it may be revealed that only patients at high risk have real benefit from early aggressive therapy, but the same approach may result in harm to patients at low risk. Tailoring therapy to the level of risk is essential to optimizing efficacy and clinical outcomes. |
doi_str_mv | 10.1016/S0002-9149(00)01480-6 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_72544871</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002914900014806</els_id><sourcerecordid>72544871</sourcerecordid><originalsourceid>FETCH-LOGICAL-e318t-df09335e188ecf4d13f26d202345a6d13978580b770449577b157cb8c07b92953</originalsourceid><addsrcrecordid>eNpdkU1vFDEMhiMEotvCTwBFICE4DNiTySRzqqqqfEiVOLSco2zG06aaSZZkZlHhz5PdLj1wsi0_tuz3ZewVwkcEbD9dAUBdddh07wE-ADYaqvYJW6FWXYUdiqds9YgcseOc70qJKNvn7AixhhZQr9ifs230vQ2OeBx4isvsA_FEW5vdMtrkf9vZx8B94PMt8ckGe0MThXmHb0qvpJn_8vMtDzFUV9dVppt9n8ayZD9r3TITdzHFYNM9z_ehT3Gi_II9G-yY6eUhnrAfny-uz79Wl9-_fDs_u6xIoJ6rfoBOCEmoNbmh6VEMddvXUItG2raUndJSw1opaJpOKrVGqdxaO1Drru6kOGHvHvZuUvy5UJ7N5LOjcbSB4pKNqmXTaIUFfPMfeBeXFMptphYgZFu3TYFeH6BlPVFvNslP5S3zT9MCvD0ARUM7Dqmo6_Mjp5WUYkedPlBUPt96Sia7Iqaj3idys-mjNwhm57XZe212RhoAs_fatOIvUqaauA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230356264</pqid></control><display><type>article</type><title>Avoidance of routine revascularization in the management of patients with non-ST-segment elevation acute coronary syndromes</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Boden, William E</creator><creatorcontrib>Boden, William E</creatorcontrib><description>A debate continues over whether a routine invasive or a conservative strategy is the best treatment approach for patients with non–ST-segment elevation acute coronary syndrome. The fundamental question underlying this debate is whether risk stratification should be an anatomy-driven or an ischemia-driven process. An early routine invasive or “drive-through” strategy, which consists of cardiac catheterization followed by percutaneous coronary intervention within 24 hours of the onset of angina, has not been shown to result in improved outcomes. In fact, investigators in the Veterans Affairs Non–Q-Wave Infarction Strategies in Hospital (VANQWISH) trial found that aggressively treated patients had significantly worse outcomes during the first year of follow-up than did those treated with a conservative strategy. In this overview, a conservative (ischemia-guided) strategy with aggressive medical therapy is recommended for patients with non–ST-segment elevation acute coronary syndrome. This conservative treatment includes intensive antiplatelet, antithrombotic, and anti-ischemic therapy combined with careful clinical assessment and provocative testing. Patients undergo catheterization and revascularization only if spontaneous angina occurs or there is objective evidence of stress-induced myocardial ischemia. In the future, it may be revealed that only patients at high risk have real benefit from early aggressive therapy, but the same approach may result in harm to patients at low risk. Tailoring therapy to the level of risk is essential to optimizing efficacy and clinical outcomes.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/S0002-9149(00)01480-6</identifier><identifier>PMID: 11206018</identifier><identifier>CODEN: AJCDAG</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Angina pectoris ; Angina, Unstable - drug therapy ; Angina, Unstable - mortality ; Biological and medical sciences ; Blood. Blood coagulation. Reticuloendothelial system ; Cardiology ; Clinical outcomes ; Health risk assessment ; Humans ; Medical sciences ; Myocardial Infarction - drug therapy ; Myocardial Infarction - mortality ; Pharmacology. Drug treatments ; Randomized Controlled Trials as Topic ; Risk Assessment ; Survival Analysis ; Syndrome ; Therapy ; Thrombolytic Therapy ; Treatment Outcome</subject><ispartof>The American journal of cardiology, 2000-12, Vol.86 (12), p.42-47</ispartof><rights>2000 Excerpta Medica Inc.</rights><rights>2001 INIST-CNRS</rights><rights>Copyright Elsevier Sequoia S.A. Dec 28, 2000</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/S0002-9149(00)01480-6$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,777,781,786,787,3537,23911,23912,25121,27905,27906,45976</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=875538$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11206018$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Boden, William E</creatorcontrib><title>Avoidance of routine revascularization in the management of patients with non-ST-segment elevation acute coronary syndromes</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>A debate continues over whether a routine invasive or a conservative strategy is the best treatment approach for patients with non–ST-segment elevation acute coronary syndrome. The fundamental question underlying this debate is whether risk stratification should be an anatomy-driven or an ischemia-driven process. An early routine invasive or “drive-through” strategy, which consists of cardiac catheterization followed by percutaneous coronary intervention within 24 hours of the onset of angina, has not been shown to result in improved outcomes. In fact, investigators in the Veterans Affairs Non–Q-Wave Infarction Strategies in Hospital (VANQWISH) trial found that aggressively treated patients had significantly worse outcomes during the first year of follow-up than did those treated with a conservative strategy. In this overview, a conservative (ischemia-guided) strategy with aggressive medical therapy is recommended for patients with non–ST-segment elevation acute coronary syndrome. This conservative treatment includes intensive antiplatelet, antithrombotic, and anti-ischemic therapy combined with careful clinical assessment and provocative testing. Patients undergo catheterization and revascularization only if spontaneous angina occurs or there is objective evidence of stress-induced myocardial ischemia. In the future, it may be revealed that only patients at high risk have real benefit from early aggressive therapy, but the same approach may result in harm to patients at low risk. Tailoring therapy to the level of risk is essential to optimizing efficacy and clinical outcomes.</description><subject>Angina pectoris</subject><subject>Angina, Unstable - drug therapy</subject><subject>Angina, Unstable - mortality</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Cardiology</subject><subject>Clinical outcomes</subject><subject>Health risk assessment</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Myocardial Infarction - drug therapy</subject><subject>Myocardial Infarction - mortality</subject><subject>Pharmacology. Drug treatments</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Risk Assessment</subject><subject>Survival Analysis</subject><subject>Syndrome</subject><subject>Therapy</subject><subject>Thrombolytic Therapy</subject><subject>Treatment Outcome</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU1vFDEMhiMEotvCTwBFICE4DNiTySRzqqqqfEiVOLSco2zG06aaSZZkZlHhz5PdLj1wsi0_tuz3ZewVwkcEbD9dAUBdddh07wE-ADYaqvYJW6FWXYUdiqds9YgcseOc70qJKNvn7AixhhZQr9ifs230vQ2OeBx4isvsA_FEW5vdMtrkf9vZx8B94PMt8ckGe0MThXmHb0qvpJn_8vMtDzFUV9dVppt9n8ayZD9r3TITdzHFYNM9z_ehT3Gi_II9G-yY6eUhnrAfny-uz79Wl9-_fDs_u6xIoJ6rfoBOCEmoNbmh6VEMddvXUItG2raUndJSw1opaJpOKrVGqdxaO1Drru6kOGHvHvZuUvy5UJ7N5LOjcbSB4pKNqmXTaIUFfPMfeBeXFMptphYgZFu3TYFeH6BlPVFvNslP5S3zT9MCvD0ARUM7Dqmo6_Mjp5WUYkedPlBUPt96Sia7Iqaj3idys-mjNwhm57XZe212RhoAs_fatOIvUqaauA</recordid><startdate>20001228</startdate><enddate>20001228</enddate><creator>Boden, William E</creator><general>Elsevier Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7TS</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20001228</creationdate><title>Avoidance of routine revascularization in the management of patients with non-ST-segment elevation acute coronary syndromes</title><author>Boden, William E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e318t-df09335e188ecf4d13f26d202345a6d13978580b770449577b157cb8c07b92953</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Angina pectoris</topic><topic>Angina, Unstable - drug therapy</topic><topic>Angina, Unstable - mortality</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Cardiology</topic><topic>Clinical outcomes</topic><topic>Health risk assessment</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Myocardial Infarction - drug therapy</topic><topic>Myocardial Infarction - mortality</topic><topic>Pharmacology. Drug treatments</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Risk Assessment</topic><topic>Survival Analysis</topic><topic>Syndrome</topic><topic>Therapy</topic><topic>Thrombolytic Therapy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Boden, William E</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Physical Education Index</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Boden, William E</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Avoidance of routine revascularization in the management of patients with non-ST-segment elevation acute coronary syndromes</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>2000-12-28</date><risdate>2000</risdate><volume>86</volume><issue>12</issue><spage>42</spage><epage>47</epage><pages>42-47</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><coden>AJCDAG</coden><abstract>A debate continues over whether a routine invasive or a conservative strategy is the best treatment approach for patients with non–ST-segment elevation acute coronary syndrome. The fundamental question underlying this debate is whether risk stratification should be an anatomy-driven or an ischemia-driven process. An early routine invasive or “drive-through” strategy, which consists of cardiac catheterization followed by percutaneous coronary intervention within 24 hours of the onset of angina, has not been shown to result in improved outcomes. In fact, investigators in the Veterans Affairs Non–Q-Wave Infarction Strategies in Hospital (VANQWISH) trial found that aggressively treated patients had significantly worse outcomes during the first year of follow-up than did those treated with a conservative strategy. In this overview, a conservative (ischemia-guided) strategy with aggressive medical therapy is recommended for patients with non–ST-segment elevation acute coronary syndrome. This conservative treatment includes intensive antiplatelet, antithrombotic, and anti-ischemic therapy combined with careful clinical assessment and provocative testing. Patients undergo catheterization and revascularization only if spontaneous angina occurs or there is objective evidence of stress-induced myocardial ischemia. In the future, it may be revealed that only patients at high risk have real benefit from early aggressive therapy, but the same approach may result in harm to patients at low risk. Tailoring therapy to the level of risk is essential to optimizing efficacy and clinical outcomes.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>11206018</pmid><doi>10.1016/S0002-9149(00)01480-6</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0002-9149 |
ispartof | The American journal of cardiology, 2000-12, Vol.86 (12), p.42-47 |
issn | 0002-9149 1879-1913 |
language | eng |
recordid | cdi_proquest_miscellaneous_72544871 |
source | MEDLINE; Elsevier ScienceDirect Journals |
subjects | Angina pectoris Angina, Unstable - drug therapy Angina, Unstable - mortality Biological and medical sciences Blood. Blood coagulation. Reticuloendothelial system Cardiology Clinical outcomes Health risk assessment Humans Medical sciences Myocardial Infarction - drug therapy Myocardial Infarction - mortality Pharmacology. Drug treatments Randomized Controlled Trials as Topic Risk Assessment Survival Analysis Syndrome Therapy Thrombolytic Therapy Treatment Outcome |
title | Avoidance of routine revascularization in the management of patients with non-ST-segment elevation acute coronary syndromes |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T07%3A28%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Avoidance%20of%20routine%20revascularization%20in%20the%20management%20of%20patients%20with%20non-ST-segment%20elevation%20acute%20coronary%20syndromes&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Boden,%20William%20E&rft.date=2000-12-28&rft.volume=86&rft.issue=12&rft.spage=42&rft.epage=47&rft.pages=42-47&rft.issn=0002-9149&rft.eissn=1879-1913&rft.coden=AJCDAG&rft_id=info:doi/10.1016/S0002-9149(00)01480-6&rft_dat=%3Cproquest_pubme%3E72544871%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=230356264&rft_id=info:pmid/11206018&rft_els_id=S0002914900014806&rfr_iscdi=true |